Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Malignant Lymphoma

Free Subscription Articles published in Bone Marrow Transplant Retrieve available abstracts of 58 articles: HTML format

Single Articles

January 2026
1. CANELO-VILASECA M, Sabbah M, Cristinelli C, Come B, et al
   Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?
   Bone Marrow Transplant. 2026 Jan 8. doi: 10.1038/s41409-025-02754.
   PubMed    
   
   
   
2. LOPEZ-PEREIRA P, Bazarbachi A, Marcais A, Ngoya M, et al
   Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP.
   Bone Marrow Transplant. 2026 Jan 3. doi: 10.1038/s41409-025-02783.
   PubMed     Abstract available
   
   
   December 2025
3. PUCKRIN R, Sapon-Cousineau V, Peters A, Owen C, et al
   Real-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.
   Bone Marrow Transplant. 2025 Dec 26. doi: 10.1038/s41409-025-02786.
   PubMed    
   
   
   
4. CHANG YS, Hsieh WC, Chang HM, Ko BS, et al
   Impact of early failure of induction on transplant outcomes in Hodgkin lymphoma.
   Bone Marrow Transplant. 2025 Dec 18. doi: 10.1038/s41409-025-02773.
   PubMed    
   
   
   
5. EASTON N, Goldfarb DG, El-Naas A, Kam R, et al
   Age 60 or older is an independent predictor of outcomes after thiotepa-based autologous transplant in primary CNS lymphoma: a CIBMTR analysis.
   Bone Marrow Transplant. 2025 Dec 5. doi: 10.1038/s41409-025-02758.
   PubMed    
   
   
   
6. DAMAJ G, de Masson A, Dreger P, Bazarbachi A, et al
   Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee.
   Bone Marrow Transplant. 2025;60:1565-1573.
   PubMed     Abstract available
   
   
   November 2025
7. LOPEZ-PEREIRA P, Romero Dominguez S, Martin-Moro F, Caballero AC, et al
   Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis.
   Bone Marrow Transplant. 2025 Nov 27. doi: 10.1038/s41409-025-02772.
   PubMed    
   
   
   
8. CORONA M, Brown S, Rejeski K, Flynn JR, et al
   Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact.
   Bone Marrow Transplant. 2025 Nov 18. doi: 10.1038/s41409-025-02745.
   PubMed     Abstract available
   
   
   
9. LINDAUER M, Reissfelder F, Hegenbart U, Luft T, et al
   Long-term disease control of monomorphic epitheliotrophic intestinal T-cell lymphoma (MEITL) with CNS involvement in a caucasian patient by allogeneic hematopoietic cell transplantation.
   Bone Marrow Transplant. 2025 Nov 15. doi: 10.1038/s41409-025-02747.
   PubMed    
   
   
   
10. KURIYAMA K, Watanabe M, Okatani T, Ota S, et al
    Outcomes of hematopoietic stem cell transplantation for patients with monomorphic epitheliotropic intestinal T-cell lymphoma: retrospective study from the Adult Lymphoma Working Group of the Japan Society for Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2025 Nov 15. doi: 10.1038/s41409-025-02752.
    PubMed    
    
    
    September 2025
11. TORRENT A, Morgades M, Iacoboni G, Reguera JL, et al
    Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy.
    Bone Marrow Transplant. 2025 Sep 30. doi: 10.1038/s41409-025-02722.
    PubMed    
    
    
    August 2025
12. DONG Y, Yang T, Zhao M, Song F, et al
    Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2025 Aug 20. doi: 10.1038/s41409-025-02691.
    PubMed     Abstract available
    
    
    June 2025
13. BEKADJA MA, Niederwieser D, Kharfan-Dabaja MA, El Fakih R, et al
    Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2025 Jun 30. doi: 10.1038/s41409-025-02664.
    PubMed    
    
    
    
14. DHOLARIA B, Bhaskar ST, Patel VG, Biltibo E, et al
    Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial.
    Bone Marrow Transplant. 2025;60:769-772.
    PubMed     Abstract available
    
    
    May 2025
15. ABDUL WAHID SF, Ismail NA, Md Fauzi MF, Mohd Idris MR, et al
    Clinical outcomes of a new local CD19 CAR-T cell therapy for patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma in Malaysia.
    Bone Marrow Transplant. 2025 May 27. doi: 10.1038/s41409-025-02629.
    PubMed    
    
    
    April 2025
16. ABRAMOVICH A, Adam E, Shapira A, Hutt D, et al
    CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma.
    Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02615.
    PubMed     Abstract available
    
    
    
17. MARTINEZ C, Khvedelidze I, Fekom M, Deau Fischer B, et al
    Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA,
    Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02568.
    PubMed     Abstract available
    
    
    
18. DREGER P, Ahmed S, Bazarbachi A, Dietrich S, et al
    How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.
    Bone Marrow Transplant. 2025 Apr 14. doi: 10.1038/s41409-025-02599.
    PubMed     Abstract available
    
    
    
19. SUREDA A, Pavlovsky A, Haidar D, Kristo F, et al
    Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02557.
    PubMed     Abstract available
    
    
    
20. ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
    Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study by the ATL working group of the Japanese Society for
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02563.
    PubMed    
    
    
    March 2025
21. CANELO-VILASECA M, Sabbah M, Di Blasi R, Cristinelli C, et al
    Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.
    Bone Marrow Transplant. 2025 Mar 27. doi: 10.1038/s41409-025-02539.
    PubMed     Abstract available
    
    
    
22. KHARFAN-DABAJA MA, Mohty R, Easwar N, Johnston P, et al
    Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.
    Bone Marrow Transplant. 2025 Mar 1. doi: 10.1038/s41409-025-02541.
    PubMed     Abstract available
    
    
    
23. LOSI G, Mussetti A, Pena M, Lopez-Pereira P, et al
    Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas.
    Bone Marrow Transplant. 2025;60:259-269.
    PubMed     Abstract available
    
    
    February 2025
24. KRAMER I, Konig L, Luft T, Hegenbart U, et al
    Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2025 Feb 13. doi: 10.1038/s41409-025-02522.
    PubMed     Abstract available
    
    
    
25. ZHOU J, Wang F, Yang S, Zhang Y, et al
    Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm.
    Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02528.
    PubMed     Abstract available
    
    
    
26. CORONA M, Ip A, Brown S, Luna A, et al
    Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma.
    Bone Marrow Transplant. 2025 Feb 1. doi: 10.1038/s41409-025-02519.
    PubMed     Abstract available
    
    
    December 2024
27. YU F, Niu J, Yang J, Hou J, et al
    Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.
    Bone Marrow Transplant. 2024 Dec 20. doi: 10.1038/s41409-024-02500.
    PubMed     Abstract available
    
    
    
28. RAMDIAL J, Lin R, Thall PF, Valdez BC, et al
    High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
    Bone Marrow Transplant. 2024;59:1754-1762.
    PubMed     Abstract available
    
    
    November 2024
29. MAINGUY A, Soussain C, Touitou V, Bennedjai A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.
    Bone Marrow Transplant. 2024 Nov 19. doi: 10.1038/s41409-024-02477.
    PubMed     Abstract available
    
    
    
30. RICHARDSON T, Tharmaseelan H, Frenzel L, Godel P, et al
    Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma.
    Bone Marrow Transplant. 2024 Nov 15. doi: 10.1038/s41409-024-02472.
    PubMed    
    
    
    
31. ZHANG X, Xu K, Gale RP, Pan B, et al
    Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2024 Nov 12. doi: 10.1038/s41409-024-02463.
    PubMed     Abstract available
    
    
    October 2024
32. BRAMANTI S, Mannina D, Chiappella A, Casadei B, et al
    Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study.
    Bone Marrow Transplant. 2024 Oct 9. doi: 10.1038/s41409-024-02427.
    PubMed     Abstract available
    
    
    
33. BEKADJA MA, Niederwiser D, Kharfan-Dabaja MA, El Fakih R, et al
    Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2024 Oct 7. doi: 10.1038/s41409-024-02431.
    PubMed     Abstract available
    
    
    September 2024
34. NISHIKUBO M, Shimomura Y, Nakaya Y, Shinohara A, et al
    Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2024 Sep 25. doi: 10.1038/s41409-024-02423.
    PubMed     Abstract available
    
    
    August 2024
35. STEWART C, Owen C, Shafey M, Perry S, et al
    Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era.
    Bone Marrow Transplant. 2024 Aug 20. doi: 10.1038/s41409-024-02399.
    PubMed    
    
    
    
36. BEER SA, Mohle R, Tabatabai G, Merle DA, et al
    Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation.
    Bone Marrow Transplant. 2024 Aug 9. doi: 10.1038/s41409-024-02382.
    PubMed     Abstract available
    
    
    April 2024
37. DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al
    Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283.
    PubMed    
    
    
    March 2024
38. MORRIS SL, Thomas BR, Palanicawandar R, Whittaker S, et al
    Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
    Bone Marrow Transplant. 2024 Mar 12. doi: 10.1038/s41409-024-02236.
    PubMed     Abstract available
    
    
    
39. GIRARD L, Koh YJ, Koh LP, Chee YL, et al
    Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02254.
    PubMed     Abstract available
    
    
    February 2024
40. NAKAYA Y, Nakamae H, Nishikubo M, Kondo E, et al
    Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02229.
    PubMed     Abstract available
    
    
    
41. HIROSE A, Koh H, Nakamae M, Nakashima Y, et al
    A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02231.
    PubMed    
    
    
    
42. MOSER O, Ngoya M, Galimard JE, Dalissier A, et al
    Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study.
    Bone Marrow Transplant. 2024 Feb 8. doi: 10.1038/s41409-024-02226.
    PubMed     Abstract available
    
    
    
43. AHMADI P, Ghandili S, Jakobs F, Konnopka C, et al
    Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
    Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02228.
    PubMed    
    
    
    January 2024
44. DE PHILIPPIS C, Zucchinetti C, Mannina D, Krampera M, et al
    Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 25. doi: 10.1038/s41409-024-02205.
    PubMed    
    
    
    
45. CHEN W, Shi J, Luo Y, Yu J, et al
    Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191.
    PubMed    
    
    
    
46. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
    Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
    PubMed     Abstract available
    
    
    
47. OLUWOLE OO, Forcade E, Munoz J, de Guibert S, et al
    Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
    Bone Marrow Transplant. 2024 Jan 4. doi: 10.1038/s41409-023-02169.
    PubMed     Abstract available
    
    
    
48. CABRERO M, Lopez-Corral L, Jarque I, de la Cruz-Vicente F, et al
    Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
    Bone Marrow Transplant. 2024 Jan 2. doi: 10.1038/s41409-023-02171.
    PubMed     Abstract available
    
    
    December 2023
49. ZHANG X, Pang Y, Wei C, Liang D, et al
    Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
    Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
    PubMed    
    
    
    
50. EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al
    Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
    Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176.
    PubMed     Abstract available
    
    
    
51. JINDAL N, C M, Mathew LJ, Kumbhalwar K, et al
    Fertility outcomes in patients desiring conception following autologous stem cell transplantation for hodgkin lymphoma using LACE conditioning.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02179.
    PubMed    
    
    
    
52. KATO K, Sugio T, Ikeda T, Yoshitsugu K, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02156.
    PubMed     Abstract available
    
    
    November 2023
53. IQBAL M, Jagadeesh D, Chavez J, Khurana A, et al
    Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Bone Marrow Transplant. 2023 Nov 16. doi: 10.1038/s41409-023-02148.
    PubMed     Abstract available
    
    
    
54. PENA M, Montane C, Paviglianiti A, Hurtado L, et al
    Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.
    Bone Marrow Transplant. 2023;58:1282-1285.
    PubMed    
    
    
    October 2023
55. GOYAL A, O'Leary D, Foss F
    Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2023 Oct 18. doi: 10.1038/s41409-023-02122.
    PubMed     Abstract available
    
    
    
56. KORESAWA-SHIMIZU R, Suzuki R, Uehara Y, Hiramoto N, et al
    Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry.
    Bone Marrow Transplant. 2023 Oct 7. doi: 10.1038/s41409-023-02118.
    PubMed    
    
    
    September 2023
57. ALEIXO GFP, Wei W, Chen PH, Gandhi NS, et al
    The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2023 Sep 12. doi: 10.1038/s41409-023-02104.
    PubMed     Abstract available
    
    
    
58. BAUR K, Buser A, Jeker LT, Khanna N, et al
    CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas.
    Bone Marrow Transplant. 2023;58:1048-1050.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.